Clinical Trials Logo

Corneal Diseases clinical trials

View clinical trials related to Corneal Diseases.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05700864 Withdrawn - Neuropathy Clinical Trials

NGF Treatment for Patients With Neuropathic Corneal Pain

Start date: November 1, 2022
Phase: Phase 1
Study type: Interventional

This prospective, single center, interventional, open-label, single arm, non-randomized trial seeks to investigate the efficacy of Oxervate® (cenergermin 0.002% eye drops) on ameliorating the signs and symptoms of neuropathic corneal pain (NCP). The study aims to enroll 28 subjects with NCP. All patients will be evaluated for clinical symptoms and signs of NCP, corneal staining and nerve regeneration (by IVCM) at Baseline (Visit 2) through the end of study (16 weeks post treatment).

NCT ID: NCT05052554 Withdrawn - Corneal Diseases Clinical Trials

Study With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium Molecular Biomarker(s) in Subjects With FECD3

Fuchs Focus
Start date: August 10, 2021
Phase: Phase 1
Study type: Interventional

PQ-504a-001 (Fuchs Focus) is an open-label, single-dose, exploratory study to evaluate safety, tolerability, and corneal endothelium molecular biomarker(s) in subjects with Fuchs Endothelial Corneal Dystrophy with Trinucleotide Repeat Expansion in the TCF4 gene (FECD3).

NCT ID: NCT03421548 Withdrawn - Glaucoma Clinical Trials

Implantable Intraocular Pressure Sensor for Glaucoma Monitoring in Patients With Boston Keratoprosthesis Type 1

BKPro
Start date: November 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety and performance of the EYEMATE system in patients undergoing concomitant implantation of a BKPro type 1 and an EYEMATE sensor over the 24 months period beginning at implantation.

NCT ID: NCT02374723 Withdrawn - Corneal Disease Clinical Trials

Evaluation of Biosynthetic Constructs to Replace Donor Corneas

Start date: June 2015
Phase: Phase 1
Study type: Interventional

Constructs made from cross-linked Human Recombinant Collagen type III are being used instead of human donor corneas in 6 patients at Deep anterior lamellar cornea grafting. Six patients serve as controls and are receiving human donor corneas using the same surgical technique. The twelve patients will be recruited from the local waiting list for patients to be undergoing corneal grafting. If the patients meet the inclusion criteria and agree to participate following oral and written consent, they will be randomized to either group. The patients will be followed for 12 months and documented with OCT, In Vivo Confocal Microscopy, slit lamp photography a o. The study is planned as a safety study with initial efficacy documentation.

NCT ID: NCT01643252 Withdrawn - Corneal Ectasia Clinical Trials

Safety and Efficacy Study for Corneal Collagen Cross-Linking in Eyes With Corneal Ectasia After Refractive Surgery

Start date: July 2012
Phase: Phase 3
Study type: Interventional

The objectives of this study are to evaluate the safety and efficacy of corneal collagen cross-linking performed with VibeX (riboflavin ophthalmic solution) and the KXL System as compared to placebo in impeding the progression of, and/or reducing, maximum corneal curvature.

NCT ID: NCT00679666 Withdrawn - Corneal Ectasia Clinical Trials

Corneal Crosslinking in Keratoconus and Corneal Ectasia

CXL
Start date: April 2008
Phase: Phase 2/Phase 3
Study type: Interventional

Prospective, randomized, single site to determine the safety and effectiveness of performing corneal collagen cross-linking (CXL) using riboflavin and UVA light in eyes progressive keratoconus or corneal ectasia.